SCLERO.ORG
Search
Scleroderma Newsroom
ISN News Manager: Jo Frowde
Autoimmune
Media Stories
Scleroderma
ISN/Website
Autoimmune Archive
We maintain news archives for the most recent 3 years.
2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
2021 - 2020 - 2019 - 2018

November 2018 Autoimmune News

Case Reports: Scleredema of Buschke associated with lichen sclerosus. Both lichen sclerosus et atrophicus with scleredema adultorum of Buschke could be considered part of the spectrum of sclerodermoid disorders with common underlying pathogenetic mechanisms. PubMed, Indian J Dermatol Venereol Leprol. (Also see Lichen Sclerosus and Scleredema Adultorum Buschke)

Smoking Is a Risk Factor for Relapse of Antimyeloperoxidase Antibodies–Associated Vasculitis. Smoking is a significant and dose–dependent risk factor for relapse of microscopic polyangiitis (MPA) and patients with MPA who smoke should be encouraged to quit. PubMed, J Clin Rheumatol, 2018 Oct;24(7):361-367. (Also see Vasculitis)

Histopathology of the skin in rheumatic diseases. In this review, we discuss the clinical features, diagnostic evaluation and the histopathological features of skin manifestation of the most relevant rheumatological autoimmune diseases. PubMed, Reumatismo, 2018 Oct 3;70(3):187-198. (Also see Skin Disease Directory)

Serum miRNA-371b-5p and miRNA-5100 (MicroRNAs) act as biomarkers for systemic lupus erythematosus (SLE). These results suggested that miR-371b-5p and miR-5100 may act as serum biomarkers for SLE. ScienceDirect, Clinical Immunology, 10/07/2018. (Also see Diagnosis of Lupus)

Mortality and causes of death across the systemic connective tissue diseases (CTDs) and the primary systemic vasculitides (PSVs). We observed premature deaths across the spectrum of CTDs and PSVs, with highest standard mortality ratios in diffuse scleroderma and anti–synthetase syndrome. PubMed, Rheumatology (Oxford), 10/03/2018. (Also see Connective Tissue Disease and Vasculitis)

Progressive reduction of serum complement levels: a risk factor for relapse in patients with hypocomplementemia in systemic lupus erythematosus (SLE). Simultaneous progressive reductions in complement levels and increases in anti-dsDNA antibody levels may indicate future relapse of serologically active clinically quiescent–SLE patients. PubMed, Lupus, 2018 Oct 11:961203318804892. (Also see Research on Systemic Lupus Erythematosus)

Relationship between interstitial CD34 positive cells and active phase of lupus nephritis. A strong interstitial expression of CD34 was observed in lower activity indices and it could play a protective role in lupus nephritis and could reduce renal activity. PubMed, Eur J Rheumatol, 2018 Oct 10:1-4. (Also see Symptoms and Complications of Lupus)

Case Report: Treatment of colon cancer in a patient with systemic lupus erythematosus. This report provides an effective way to diagnose colon cancer in patients with systemic lupus erythematous and illustrates a successful therapy strategy for this complex medical condition. PubMed, BMC Cancer. (Also see Symptoms and Complications of Lupus and Cancer)

Patients' perspective of the effectiveness and acceptability of pharmacological and non–pharmacological treatments of fibromyalgia. This article presents results from a large online survey on fibromyalgia patient perspectives of pharmacological and non–pharmacological treatments. PubMed, Scand J Pain, 10/13/2018. (Also see Treatments for Fibromyalgia)

Frequency of audiological complaints in patients with fibromyalgia syndrome (FMS) and its relationship with oxidative stress. Patients with FMS have high levels of oxidative stress markers, highly frequent audiological symptoms with high hearing frequencies in audiometry, independent of disease severity. PubMed, Niger J Clin Pract, 2018 Oct;21(10):1271-1277. (Also see Fibromyalgia and Oxidative Stress)

Go to Autoimmune News: October 2018
 
 

SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses. We are a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team. Donations may also be mailed to:

International Scleroderma Network (ISN)
7455 France Ave So #266
Edina, MN 55435-4702 USA
Email [email protected]. Disclaimer. Privacy Policy.